MRVI logo

MARAVAI LIFESCIENCES HLDGS-A

MRVINASDAQ
๐Ÿ† #1842 by market capEarnings Nov 4 ยท PostUS Equity
$8.46โ–ผ $0.05 (โˆ’0.53%)
Market closed ยท at close
๐Ÿ””
Track MRVI
Get earnings, price moves & breaking news on Telegram
Track
24hโ–ผ 0.5%
7dโ–ฒ 15.4%
14dโ–ฒ 24.3%
30dโ–ฒ 10.3%
ytdโ–ฒ 159.5%
1yโ–ฒ 169.4%
๐ŸฆMarket Cap
$2.20B
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
-3.3%
Declining
๐Ÿ“ŠGross Margin
34.9%
Moderate
๐Ÿ’ตFCF Margin
3.8%
Moderate
โš–๏ธP/S Ratio
10.5x
Elevated
Otter Score
โ€”
Insufficient data

Trading Snapshot

Day Range
$8.29 โ€“ $8.56
52-Week Range
$2.55 โ€“ $9.42
Volume (shares)
102,814
Avg Volume (shares)
โ€”
Shares Outstanding
259.7M
Next Earnings
2026-11-04

Fundamentals Snapshot

Annual Revenue
$186M
Last Q Revenue
$51M
P/E Ratio
โ€”
P/S Ratio
10.5x
EPS (TTM)
$-0.53
Dividend Yield
โ€”
MRVI logo

MARAVAI LIFESCIENCES HLDGS-A

MRVI
Financial Trends

Financial history unavailable.

StockOtter ยท stockotter.space

About MARAVAI LIFESCIENCES HLDGS-A

Maravai LifeSciences Holdings, Inc. is a life sciences company operating globally, supplying essential products that facilitate the advancement of drug therapies, diagnostics, innovative vaccines, and research into human diseases. Its diverse product line supports critical stages of biopharmaceutical development, featuring nucleic acids for both diagnostic and therapeutic applications, antibody-based solutions for detecting impurities in biopharmaceutical manufacturing, and tools for monitoring protein expression across different tissue types. The company conducts its operations through two distinct segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment specializes in manufacturing and distributing products integral to gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics. This encompasses reagents utilized in the chemical synthesis, modification, labeling, and purification of DNA and RNA. Additionally, this division provides messenger RNA, oligonucleotides, their foundational building blocks, plasmid DNA, and the proprietary CleanCap capping technology. Meanwhile, the Biologics Safety Testing segment offers analytical products vital for developing biologic manufacturing processes. Its offerings include bespoke antibody and assay development services tailored to specific products, alongside HCP ELISA kits, various other ELISA kits for identifying bioprocess impurities and contaminants, ancillary reagents, and custom service solutions. Maravai's clientele spans biopharmaceutical companies, other life sciences and biopharmaceutical research firms, academic research institutions, and in vitro diagnostics companies. Incorporated in 2020, Maravai LifeSciences Holdings, Inc. maintains its headquarters in San Diego, California.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
โšกMomentumโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Insufficient data
โ€”/100

Analyst Ratings

โ“˜
Consensus
Buy
14 analysts
Strong Buy4
Buy5
Hold5
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.